Currently approved and select investigational PI3Kis in CLL and other hematologic malignancies
| Drug . | PI3K isoform selectivity . | Status . | Approved dosing . |
|---|---|---|---|
| Idelalisib | PI3Kδ | FDA approved for patients with R/R CLL for whom rituximab monotherapy is appropriate and in patients with SLL or FL after ≥2 prior therapies | 150 mg by mouth twice daily |
| Duvelisib | PI3Kγ/δ | FDA approved for R/R CLL, SLL, and FL after ≥2 prior therapies | 25 mg by mouth twice daily |
| Copanlisib | PI3Kα/δ | FDA approved for relapsed follicular lymphoma after ≥2 prior therapies | 60 mg IV on days 1, 8, and 15 of a 28-d treatment cycle |
| Umbralisib | PI3Kδ | Investigational | Not applicable |
| MEI-401 | PI3Kδ | Investigational | Not applicable |
| Parsaclisib | PI3Kδ | Investigational | Not applicable |
| Drug . | PI3K isoform selectivity . | Status . | Approved dosing . |
|---|---|---|---|
| Idelalisib | PI3Kδ | FDA approved for patients with R/R CLL for whom rituximab monotherapy is appropriate and in patients with SLL or FL after ≥2 prior therapies | 150 mg by mouth twice daily |
| Duvelisib | PI3Kγ/δ | FDA approved for R/R CLL, SLL, and FL after ≥2 prior therapies | 25 mg by mouth twice daily |
| Copanlisib | PI3Kα/δ | FDA approved for relapsed follicular lymphoma after ≥2 prior therapies | 60 mg IV on days 1, 8, and 15 of a 28-d treatment cycle |
| Umbralisib | PI3Kδ | Investigational | Not applicable |
| MEI-401 | PI3Kδ | Investigational | Not applicable |
| Parsaclisib | PI3Kδ | Investigational | Not applicable |
FDA, U.S. Food and Drug Administration.